Delcath SystemsDCTH
Market Cap: $271M
About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Employees: 76
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
100% more capital invested
Capital invested by funds: $40.4M [Q1] → $80.9M (+$40.5M) [Q2]
86% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $839K
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
44% more funds holding
Funds holding: 36 [Q1] → 52 (+16) [Q2]
3.14% more ownership
Funds ownership: 34.61% [Q1] → 37.75% (+3.14%) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Stephens & Co. Sudan Loganathan 33% 1-year accuracy 3 / 9 met price target | 159%upside $25 | Overweight Reiterated | 6 Aug 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target | 128%upside $22 | Buy Reiterated | 6 Aug 2024 |
Craig-Hallum Chase Knickerbocker 44% 1-year accuracy 8 / 18 met price target | 86%upside $18 | Buy Initiated | 28 Jun 2024 |
Financial journalist opinion
Based on 9 articles about DCTH published over the past 30 days